Role of Cyclooxygenase-2 in the Development and Growth of Schwannomas

Abstract

Recently, numerous experimental reports as well as clinical trials suggested a possible therapeutic role of selective cyclooxygenase-2 (COX-2) inhibitors in the treatment of various tumors. COX-2 is known to convert procarcinogens to carcinogens and is upregulated in several malignant tumors. Its overexpression seems to correlate with aggressive disease and poor survival. In human schwannomas, COX-2 expression was observed in the cytoplasma and perinuclear regions of tumor cells. The available data suggests involvement of COX-2 in the development and growth of human schwannomas by regulating angiogenic factors and inhibition of tumor cell apoptosis by production of prostaglandins, particularly PGE2. Furthermore, diverse neurotrophic factors have been also suggested a biological role in development, maintenance, and growth of schwannomas. Selective COX-2 inhibitors have a potential role for targeted therapy against schwannomas.